Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

They showed that a TAS1R2-TAS1R3 agonist (sucralose, a zero-calorie sweetener) or a TAS1R2-TAS1R3 antagonist (lactisole, a sodium salt that inhibits sweet taste) mixed with a glucose meal acutely ...

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...

VK2735 is Viking's GLP-1 agonist, and it has achieved strong results in clinical trials. Participants in a phase 2 trial who ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib ...

South San Francisco, California Saturday, May 18, 2024, 09:00 Hrs [IST] ...

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

Mizuho analysts are betting the stock of the small biotech Terns Pharmaceuticals Inc. could rally sharply if the company’s ...

The following is a summary of “Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real ...